TMS Bioscience

Executive Summary

TMS Bioscience is a privately held, San Diego-based company founded in 2008 that specializes in the development and supply of high-quality antibodies and reagents for research and diagnostic applications. With over a decade of experience, the company has established itself as a reliable provider of critical tools that enable scientific discovery and the advancement of diagnostic assays. While the company operates in a competitive landscape with large players like Abcam and Thermo Fisher, its focus on quality and customer relationships allows it to carve out a niche in the life science tools market. The company's stage and financials are not publicly disclosed, but its longevity suggests steady operations. The growing demand for antibodies in research and companion diagnostics, particularly in oncology and infectious diseases, provides tailwinds. However, limited visibility into its pipeline and revenue makes conviction moderate.

Upcoming Catalysts (preview)

• Q3 2026Launch of novel recombinant antibody product line for immunotherapy targets70% success
• Q1 2027Strategic partnership with a diagnostic assay developer for companion diagnostic reagents50% success
• Q4 2026FDA 510(k) clearance for a custom antibody used in a diagnostic kit40% success